13) BIOPROTO
Abstract
Funds biomedical research focused on the nonclinical and early clinical development of therapeutic countermeasures against known and emerging viral, bacterial, and toxin biological warfare (BW) threats for which Food and Drug Administration (FDA)-approved therapeutics are limited or lacking. Research is focused on preclinical evaluation (e.g., in large animal models) of broad-spectrum therapeutic candidates that target pathogen directly, enhance the host response and/or relieve BW disease symptoms. Candidates that are shown to be both safe and efficacious against BW threats will advance for further clinical evaluation under RDT&E budget activity 5, and can be accelerated for use against emerging infectious diseases during an outbreak.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2025
- Source ID
- 2d9de7433ee86621db43e815ee21111b